Patent Application
20240288446
This application incorporates by reference the Sequence Listing contained in the following ASCII text file being submitted concurrently herewith:
File name: 4692-06400_BNT228327USPC_Sequence_Listing_ST25_; created on Oct. 4, 2022; and having a file size of 34 KB.
The information in the Sequence Listing is incorporated herein in its entirety for all purposes.
The present invention relates to an in-vitro process for predicting and/or detecting fibrinolytic insufficiency, preferably associated with NETs with/without disseminated intravascular coagulation (DIC), from a first biological sample comprising measuring the concentration of plasminogen and/or at least one fragment thereof. The present invention also relates to a process for determining the efficiency of a treatment of fibrinolytic insufficiency.
The present invention is applicable especially in the medical and veterinary field.
In the description below, the references between brackets ( ) refer to the reference list at the end of the text.
Septic shock is a syndrome characterized by a dysregulated inflammatory reaction of the host in response to a pathogenic agent, inducing hemodynamic dysfunction, and coagulation-fibrinolytic disorders leading to multiple organ failure syndrome.
Thrombus lysis, a major line of defense against thrombosis, is triggered by plasmin generated upon cleavage-activation of plasminogen bound to clot components, mostly fibrin or platelet membranes.(1) Plasminogen is a single-chain molecule consisting of an N-terminal region, 5 kringle (K) domains and the serine protease (SP) region.(2) K1 and K4 contain each a lysine-binding site that ensures binding of plasminogen to carboxy-terminal lysine residues of fibrin.(3) Plasminogen thus bound is cleaved at Arg561-Val562 and transformed into plasmin by the tissue-type or the urokinase-type plasminogen activators, tPA and uPA respectively, in a surface and localized dependent manner. Purposely, tPA is fully active once bound to fibrin whereas uPA preferentially operates when bound to its membrane-anchored receptor uPAR. Proteases like human neutrophil elastase (HNE) degrade plasminogen without generating plasmin (4, 5). In the circulation, HNE is rapidly inhibited by the @1-proteinase inhibitor, (α1-PI, Ka=6.5×107 M−1s−1)(6) that circulates at a high concentration (20 to 40 μM). HNE-α1PI complexes thus formed preclude proteolytic degradation of circulating plasminogen. However, experimental evidence indicates that HNE bound to negatively charged membrane proteoglycans or other macromolecules escapes inhibition and remains active.(7, 8) Belorgey and Bieth (1995, 1998)(9, 10) demonstrated that HNE forms a tight complex with DNA that strongly impairs its inhibition by α1-PI. Besides this protective action on HNE, the group of Bieth fully documented the protective action of DNA on other bound proteases.(11, 12) The extrusion into the extracellular space of functional scaffolds combining intact DNA with added-on HNE by neutrophils in a process termed neutrophil extracellular traps (NETs) formation or netosis, was discovered in 2004.(13) PMA (phorbol 12-myristate 13-acetate) and bacterial infections use a related pathway for NET induction: activation of protein kinase C and generation of reactive oxygen species.(14)
NETs are decondensed nuclear DNA fibers with bound nuclear proteins (histones), and cytoplasmic and granular proteases including HNE, cathepsin G and myeloperoxidase.(15) HNE is the most abundant (5.24 μmoles per g NET-DNA), (16) characteristic component of NETs that is bound to DNA with nanomolar affinity. (17) NETs are proteolytically active and were originally described as beneficial (16) extracellular killers of microorganisms.(18) Recent data indicate that NETs are also of pathophysiological relevance in a variety of non-infectious inflammatory disorders, including autoimmune diseases, thrombosis (19, 20) and cancer (74) The combined action of NETs and the clotting system characterizes immunothrombosis.(20) It has been shown that NETs are released during thrombus formation and are integrated together with von Willebrand factor into the fibrin scaffold. (21, 22) The presence of NETs in human coronary and cerebral thrombi has actually been demonstrated (23-25). The NETs' DNA-backbone insensitivity to plasmin and the formation of non-fibrinolytic plasmin-DNA-fibrin complexes were suggested as possible causes of fibrinolytic resistance (27, 29) favoring thrombosis.
However, there is currently no process that makes it possible to safely and systematically detect fibrinolytic insufficiency, in particular associated to netosis, in particular in infectious and non-infectious diseases. There is also no process and/or means that makes it possible to predict the occurrence, for example from a biological sample, of fibrinolytic insufficiency, in particular associated to netosis and/or DIC.
Some possible biological markers of DIC and secondary fibrinolytic response have been disclosed.
However, the known markers may be detected/used in particular conditions and/or by using complex device and/or method and/or allow to obtain results after a delay which is too long or could be too long to be useful to the patient and/or the clinician and/or doctor.
There is therefore a real need to find a process and/or means that overcomes these flaws, drawbacks and obstacles of the prior art, in particular a simple, quick and effective process making it possible to detect fibrinolytic insufficiency and fibrinolytic insufficiency associated to netosis and DIC, in order to improve the vital prognosis of individuals.
There is also a real need to find a process and/or means that overcomes these flaws, drawbacks and obstacles of the prior art, in particular a simple, quick and effective process making it possible to detect fibrinolytic insufficiency and fibrinolytic insufficiency associated to netosis and DIC, in order to improve the vital prognosis of individuals and/or reduce treatment costs for said individuals.
The aim of the present invention is to overcome the drawbacks of the prior art by providing a process for predicting and/or detecting fibrinolytic insufficiency, preferably fibrinolytic insufficiency associated to netosis and/or disseminated intravascular coagulation (DIC) from a biological sample comprising a step of detecting and/or measuring the concentration and/or content of at least one biological marker.
In the present document, “biological marker” is intended to mean at least one biological marker selected from the group comprising plasminogen or fragment thereof, and/or a protease component of NETs, preferably Human Neutrophil Elastase (HNE). Preferably the biological marker is plasminogen or fragment thereof, more preferably plasminogen and/or a protease-derived plasminogen fragment, more preferably HNE-derived plasminogen fragment.
According to the invention, the content of said at least one selected biological marker, in particular in a sample, may be measured by any suitable process known to those skilled in the art.
According to the invention, the concentration of said at least one selected biological marker, in particular in a sample, may be measured by any suitable process known to those skilled in the art.
According to the invention, said at least one selected biological marker may be detected by any suitable process known to those skilled in the art.
Since NETs may compromise thrombus lysis, the inventors investigate the role of HNE-DNA complexes on fibrinolysis. The inventors surprisingly demonstrate that in the presence of NETs containing active HNE-DNA complexes, plasminogen is reduced to fragments that inhibit plasminogen binding and plasmin formation onto fibrin resulting in impaired fibrinolysis. The inventors surprisingly demonstrate new mechanistic insights into septic shock thrombosis based on the capacity of HNE-DNA complexes to trigger a new unconventional mechanism of fibrinolytic insufficiency.
The inventors also surprisingly demonstrate that the concentration of Plasminogen is reduced in biological sample from a patient with septic shock.
The inventors also surprisingly demonstrate that the concentration of Plasminogen is reduced in biological sample from a patient with fibrinolytic insufficiency, in particular with fibrinolytic insufficiency associated to netosis and disseminated intravascular coagulation (DIC).
The inventors also surprisingly demonstrate in patients suffering from septic shock induced DIC and NETosis, plasminogen degradation by human neutrophil elastase (HNE) bound to DNA and subsequent failure to form plasmin.
The inventors have also surprisingly demonstrated that NETs induce a decrease of plasminogen concentration, in particular plasminogen concentration in the plasma, in particular in patients suffering from septic shock associated-disseminated intravascular coagulation (DIC).
An object of the present invention is an in-vitro process for predicting and/or detecting fibrinolytic insufficiency, preferably fibrinolytic insufficiency associated to NETs associated and disseminated intravascular coagulation (DIC) from a biological sample comprising measuring the concentration of Plasminogen and/or fragment thereof.
An object of the present invention is also an in-vitro process for predicting and/or detecting fibrinolytic insufficiency of different pathologies with/without disseminated intravascular coagulation (DIC) from a biological sample comprising measuring the concentration of Plasminogen and/or any fragments thereof.
An object of the present invention is also an in-vitro process for predicting and/or detecting fibrinolytic insufficiency, preferably associated to pathologies with NETs with/without disseminated intravascular coagulation (DIC), from a first biological sample comprising measuring the concentration of Plasminogen and/or at least one fragment thereof.
An object of the present invention is also an in-vitro process for predicting and/or detecting fibrinolytic insufficiency and fibrinolytic insufficiency preferably associated to disseminated intravascular coagulation (DIC) from a biological sample comprising measuring the concentration of Plasminogen and/or any fragments thereof.
An object of the present invention is also an in-vitro process for predicting and/or detecting pathology associated with NETs or Netosis, preferably sepsis, ischemic stroke, coronary thrombosis, cancer, and autoimmune diseases from a biological sample comprising measuring the concentration of plasminogen and/or fragments thereof, preferably mini-plasminogen (K5-SP).
An object of the present invention is also an in-vitro process for predicting and/or detecting fibrinolytic insufficiency, preferably of a from a biological sample comprising measuring the concentration of plasminogen and fragments thereof in patients with infectious and/or non-infectious diseases.
An object of the present invention is also an in-vitro process for predicting and/or detecting pathology associated with Netosis from a biological sample comprising measuring the concentration of plasminogen and fragments thereof.
In the present document, “netosis” is the process of neutrophil death whereas NETs refer specifically to DNA fibers with bound nuclear proteins and active enzymes, preferentially DNA-HNE complexes.
In the present document “protease component of NETs” means actives enzymes bound to DNA fibers of NETs.
In the present document “a protease-derived plasminogen fragment” means any plasminogen fragments known from on skilled in the art.
In the present document “fibrinolytic insufficiency” means any disorder and/or deficiency in the fibrinolytic process. It may be for example any deficiency that could involve fibrinolytic factors, for example plasminogen, tissue plasminogen activator [tPA], urokinase [uPA], and the inhibitors PAI-1 and a2-antiplasmin. Preferably it means fibrinolytic insufficiency, associated with neutrophil extracellular traps (NET) release, and/or with disseminated intravascular coagulation (DIC).
In the present document “disseminated intravascular coagulation” (DIC) means a condition characterized by systemic activation of coagulation, potentially leading to thrombotic obstruction of small and midsize vessels, thereby contributing to organ dysfunction, as disclosed in Blood.
In the present document “pathology associated with NETs or Netosis” means any pathology known from one skilled in the art which involved NETs or Netosis. It may be for example sepsis, ischemic stroke, coronary thrombosis, cancer, and/or autoimmune diseases. In particular it may be NETs associated with sepsis-DIC, NETs associated with acute myocardial infarction or stent thrombosis, NETs associated with ischemic stroke thrombi, NETs associated with autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis or NETs associated with breast or lung or pancreatic cancer.
In the present document “plasminogen” means a 92-kDa protein which is a single-chain molecule consisting of an N-terminal region, 5 kringle (K) domains (K1 to K5) and the serine protease (SP) region. (2) K1 and K4 contain each a lysine-binding site. In other words, “Plasminogen” is intended to mean a 92 kDa single-chain proenzyme consisting of an N-terminal region, 5 kringle (K) domains and the serine protease (SP) region. It may be for example plasminogen as described by Xue Y et al (2) and/or by Law et al. Cell Reports| Volume 1, ISSUE 3, P185-190, Mar. 29, 2012(75). It may be the protein of amino acid sequence
In the present “plasminogen fragments” means any fragments of plasminogen known from one skilled in the art. It may be for example fragments of plasminogen comprising any domain of plasminogen, for example of kringle (K) 1 to 5 domains, for example a peptide of sequence CKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDND PQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLECQAWDSQSP HAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPRCTTPPPSSGP TYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCKNLDENYCRNP DGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTEQLAPTAPPELTPVVQDCYHGDGQ SYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRNPDADKGPWCF TTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEEDCMFGNGKGYRGKRAT TVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGGPWCYTTNPRKL YDYCDVPQC (SEQ ID NO 10), or the serine protease domain (SP), for example comprising a peptide of sequence WVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVIL GAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRT ECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDS CQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMR (SEQ ID NO 11) or any combination thereof, for example a fragment composed of K1+K2+K3, for example a peptide of sequence CKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDND PQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLECQAWDSQSP HAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPRCTTPPPSSGP TYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCKNLDENYCRNP DGKRAPWCHTTNSQVRWEYCKIPSC (SEQ ID NO 7) or a fragment comprising a peptide of sequence SEQ ID NO 7, a fragment composed of K1+K2+K3+K4, for example a peptide of sequence CKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDND PQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLECQAWDSQSP HAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPRCTTPPPSSGP TYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCKNLDENYCRNP DGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTEQLAPTAPPELTPVVQDCYHGDGQ SYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRNPDADKGPWCF TTDPSVRWEYCNLKKC (SEQ ID NO 6) or a fragment comprising a peptide of sequence SEQ ID NO 6, or a fragment composed of single K4, for example a peptide of sequence CYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRNPDA DKGPWCFTTDPSVRWEYCNLKKC (SEQ ID NO 12) or a fragment comprising single K4 for example VQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRN PDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVV (SEQ ID NO 5). It may be for example a fragment composed of domains K5 and the SP also called mini-plasminogen (K5-SP), for example a peptide of sequence CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDG DVGGPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHS WPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPH VQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQ GTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLV CFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMR (SEQ ID NO 8) or a fragment comprising a peptide of sequence SEQ ID NO 8, and/or any fragment of plasminogen obtained with active protease-DNA complexes preferably HNE-DNA complexes of NETs.
In the present “HNE-derived plasminogen fragments” means fragments of plasminogen selected from the group of fragment comprising kringle 1 to 3 domains (K1+2+3), kringle 1 to 4 domains (K1+2+3+4) and/or kringle 5 domain and the serine protease (SP) region, also designated mini-plasminogen, (K5-SP). For example fragments of plasminogen comprising kringle 1 to 3 domains (K1+2+3) may be for example a peptide comprising the peptide of sequence SEQ ID NO 7, for example a peptide of sequence LFEKKVYLSECKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEE NYCRNPDNDPQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLE CQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPR CTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCK NLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPV (SEQ ID NO 2) and/or a peptide of sequence LFEKKVYLSECKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEE NYCRNPDNDPQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLE CQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPR CTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCK NLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTEQLAPTAPPELTPV (SEQ ID NO 9), fragment of plasminogen comprising kringle 1 to 4 domains (K1+2+3+4) may be for example a peptide comprising the peptide of sequence SEQ ID NO 6, for example a peptide of sequence LFEKKVYLSECKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEE NYCRNPDNDPQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLE CQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPR CTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCK NLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTEQLAPTAPPELTPVV QDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRNP DADKGPWCFTTDPSVRWEYCNLKKCSGTEASVV (SEQ ID NO 3), fragment of plasminogen comprising domains K5 and the serine protease (SP) region, also designated mini-plasminogen, (K5-SP) may be for example a peptide comprising the peptide of sequence SEQ ID NO 8, for example a peptide of sequence
In the present “cytoplasmic and granular active proteases” means cathepsin G, myeloperoxidase or elastase.
In the present “Human Neutrophil Elastase” (HNE) means Neutrophil elastase (EC 3.4.21.37), leukocyte elastase. HNE is a trypsin/chymotrypsin-type serine proteinase in the same family of others leukocyte granule-associated proteases, for example proteinase 3 and cathepsin.
In the present “DNA bound proteins” means histones, preferentially citrullinated histones, fibronectin and von Willebrand factor.
In the present document, “biological sample” is intended to mean any sample obtained from mammals, for example a mammal selected from the group comprising the orders Monotremata, Didelphimorphia, Paucituberculata, Microbiotheria, Notoryctemorphia, Dasyuromorphia, Peramelemorphia, Diprotodontia, Tubulidentata, Sirenia, Afrosoricida, Macroscelidea, Hyracoidea, Proboscidea, Cingulata, for example the armadillo, Pilosa, Scandentia, Dermoptera, Primates, Rodentia, Lagomorpha, Erinaceomorpha for example the hedgehog, Soricomorpha, Chiroptera, Pholidota, Carnivora, Perissodactyla, Artiodactyla and Cetacea. It may for example be a human or an animal. It may for example be a livestock animal, a pet, a threatened animal species or any other animal.
According to the invention, the biological sample may be a blood sample, plasma sample or any biological fluid. It may be for example a biological sample selected from the group comprising blood, plasma, urine, tears or tissue extracts. Preferably, the biological sample may be a blood sample or a plasma sample, more preferably plasma sample, it may also be a culture supernatant obtained from cultured cells in vitro.
According to the invention, the biological sample may originate from a mammal with septic shock or a risk of septic shock or any other non-infectious inflammatory process.
According to the invention, the concentration of plasminogen may be determined/measured by any method and/or process known form one skilled in the art. It may be, for example a concentration measured by antigenic or by a functional assay using either a plasminogen activator e.g. urokinase, or streptokinase-plasminogen complexes, for example as disclosed in “Criteria for specific measurement of plasminogen (enzymatic; procedure) in human plasma”, eJIFCC, vol 12 No 2, 2000 (77) or in Massberg, S., et al. “Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases”. Nat Med 16, 887-896 (45). The concentration of plasminogen may also be determined/measured with a process comprising measuring its potential fibrinolytic activity, by immunoassay, by cellular immunoassay, or flow cytometry.
For example, when the concentration of plasminogen is measured by immunoassay, the immunoassay allow to detect circulating plasminogen, when the concentration of plasminogen is measured by cellular immunoassay, the cellular immunoassay may use flow cytometry to detect plasminogen on cell surface. It may be for example an immunoassay as disclosed in Rife U, Milgrom F, Shulman S. Antigenic analysis of plasminogen and plasmin. Blood 1963,212,322 Okamoto A et al. Population based distribution of plasminogen . . . J Thromb Haemost 2003, 1, 2397 (83).
For example when the concentration of plasminogen is measured by flow it may allow to determine plasminogen binding to identify cell surface-specific plasminogen binding
For example, the concentration of plasminogen may be measured by a colorimetric method, for example colorimetric method using streptokinase as activator, for example using a commercial available kit, for example BIOPHEN Plasminogen (LRT) Ref 221511 commercialized by Hyphen Biomed, for example COAMATIC® Plasminogen Ref 82 2452 63 by Chromogenix; for example Stachrom Plasminogen 00658 by STAGO. For example, when the concentration of plasminogen is measured with BIOPHEN Plasminogen (LRT) Ref 221511, the reference or normal range is from 70 to 130%. For example, when the concentration of plasminogen is measured with COAMATIC® Plasminogen Ref 82 2452 63, the reference or normal range is from 80 to 120%. For example, when the concentration of plasminogen is measured with Stachrom Plasminogen 00658, the reference or normal range is from 80 to 120%.
For example, the concentration of plasminogen may be measured by immunoassay, for example using a commercial available kit, for example commercial kits available measure plasminogen by immunoassay, for example Technozym® Glu-Plasminogen ELISA Kit Ref TC12040 by Technoclone (Normal Glu-plasminogen values range from 60-250 μg/ml). For example the Human Plasminogen ELISA Kit (PLG) Ref ab108893 by Abcam. For example, when the concentration of plasminogen is measured with Human Plasminogen ELISA Kit (PLG), the reference or normal range of concentration of plasminogen in plasma is from 70 to 135 μg/mL.
For example, plasminogen may be measured/detected antigenic assay, for example by polyclonal and/or monoclonal antibodies, for example plasminogen Polyclonal and/or monoclonal antibodies commercially available, for example for flow cytometry to detect plasminogen on cell surface. It may be for example the antibodies commercialized with the reference PA5-14196 by Invitrogen and/or ab154560 by Abcam.
According to the invention, the concentration of fragments of plasminogen may be measured by any method and/or process known form one skilled in the art. It may be, for example a concentration measured by proteomic analysis using mass spectrophotometry or by antigenic assay using monoclonal antibodies or by any combination of methods. For example, the concentration of fragment of plasminogen comprising kringles 1-4 also called angiostatin-like may be measured by immunoassay, for example as disclosed by Lijnen et al. 2001 “Enzyme-linked Immunosorbent Assay for the Specific Detection of Angiostatin-Like Plasminogen Moieties in Biological Samples” Thromb Res 2001 102 (1), 53-9 (76). Plasminogen fragments including single K4, K1-K2-K3, K1-K2-K3-K4 or mini-plasminogen (K5-SP) may be preferably detected qualitatively by Western blot or Flow cytometry, for example using specific antibodies. It may be, for example a process as disclosed in M Sten-Linder et al. “Angiostatin Fragments in Urine From Patients With Malignant Disease” Anticancer Res 1999; 19; 3409-14 (78), or in Y Takada “Potential Role of Kringle-Integrin Interaction in Plasmin and uPA” Actions Journal of Biomedicine and Biotechnology Volume 2012, Article ID 136302, 8 pages doi: 10.1155/2012/136302 or in Z Zhang “Plasminogen Kringle 5 Inhibits Alkali-Burn-Induced Corneal Investigative” Ophthalmology & Visual Science November 2005, Vol. 46, 4062-4071. doi:https://doi.org/10.1167/iovs.04-1330-(80)
For example, when the concentration of fragment of plasminogen comprising kringles 1-4 also called angiostatin-like is measured by immunoassay, for example in tumor fluids from cancer patients, the process may comprise a removal step of other plasminogen moieties, for example by immunoadsorption, for example in samples, preferably in diluted sample.
According to the invention, the concentration of HNE-derived plasminogen fragments may be measured by any method and/or process known form one skilled in the art. It may be, for example a concentrations measured by antigenic assay using monoclonal antibodies. For example, the concentration of HNE-derived plasminogen fragments may be measured by immunoassay, for example as disclosed by Lijnen et al. 2001 (76). HNE-derived plasminogen fragments including single K4, K1-K2-K3, K1-K2-K3-K4 or mini-plasminogen (K5-SP) may be preferably detected qualitatively by Western blot or Flow cytometry, for example using specific antibodies. It may be, for example a process as disclosed in Rouy D et al. “Apolipoprotein(a) and Plasminogen Interactions With Fibrin: A Study With Recombinant Apolipoprotein(a) and Isolated Plasminogen Fragments” Biochemistry 1992; 31; 6333 (56), or in Barbosa da Cruz D et al “DNA-bound Elastase of Neutrophil Extracellular Traps Degrades Plasminogen, Reduces Plasmin Formation, and Decreases Fibrinolysis: Proof of Concept in Septic Shock Plasma” FASEB J 20189, 33, 14270 (81). The concentration and quality of HNE fragments can also for example be measured and assessed by combining immunoantigenic methods and any other method of measurement of the size or determination of aminoacid sequence of the fragment, for example by mass spectrometry as for example those combined for proteomic analysis. For example, the concentration of HNE-derived plasminogen fragments may be measured by flow cytometry to detect binding of plasmin-generated protein fragments to cells, for example as disclosed in Constantinescu et al. “Amorphous protein aggregates stimulate plasminogen activation, leading to release of cytotoxic fragments that are clients for extracellular chaperones.” J. Biol. Chem. (2017) 292(35) 14425-14437 (82).
For example, when the concentration of HNE-derived plasminogen fragments is measured by immunoassay, for example in tumor fluids from cancer patients, the process may comprise a removal step of other plasminogen moieties, for example by immunoadsorption, for example in samples, preferably in diluted sample.
According to the invention, the determination/measurement of the concentration of fragments of plasminogen comprising kringle (K) 1 to 3 domains (K1+2+3) may be carried out by any adapted method known from one skilled in the art. It may be for example by antigenic assay. For example, the concentration of fragments of plasminogen comprising kringle (K) 1 to 3 domains (K1+2+3) may be measured by immunoassay, for example as disclosed by Lijnen et al 2001 Enzyme-linked Immunosorbent Assay for the Specific Detection of Angiostatin-Like Plasminogen Moieties in Biological Samples Thromb Res 2001 102 (1), 53-9 (76).
According to the invention, the determination/measurement of the concentration of mini-plasminogen (K5-SP) or fragment of plasminogen comprising kringle (K) 5 domain and the serine protease (SP) region may be carried out by any adapted method known from one skilled in the art. It may be for example by antigenic assay. For example using a combination of protein separation and proteomic analysis by mass spectrometry. For example, the concentration of fragment of plasminogen comprising kringle (K) 5 domain and the serine protease (SP) region or mini-plasminogen (K5-SP) may be measured by immunoassay, for example as disclosed in Moroz et al. 1986 “Mini-plasminogen-likfer agments of plasminogen in synovial fluid in acute inflammatory arthritis Thromb Res 1986, 43, 417 (5).
According to the invention, the detection process may also comprise a step of comparing the measured concentration of plasminogen with a reference value. It may be for example a reference value or a reference intervals which represent usually of 95% of the value or interval of the reference healthy population, preferably determine through statistical analysis, for example as disclosed by The Clinical & Laboratory Standards Institute (CLSI).
According to the invention, the reference concentration value of plasminogen may be the concentration of plasminogen measured in a biological sample of subject, or the mean concentration value measured in a group of reference healthy subjects. Preferably, the reference concentration value of plasminogen may be the concentration of plasminogen measured in a pool of biological samples from healthy subjects. The reference concentration value of plasminogen may be internal standard defined as a biological sample of subject titrated against samples from healthy subjects. The reference concentration value of plasminogen may be for example a concentration of 1 to 2 μmol/L, preferably of 1.5 to 2 μmol/L of full-length plasminogen.
According to the invention, the reference concentration value of fragments of plasminogen may be the concentration of fragments of plasminogen measured a biological sample of subject, or the mean concentration value measured in a group of reference healthy subjects. Preferably, the reference concentration value of fragments of plasminogen may be the concentration of fragments plasminogen measured in a pool of biological samples from healthy subjects and/or in an internal standard defined as a biological sample of subject titrated against samples from healthy subjects.
According to the invention, the reference concentration value of fragments plasminogen comprising kringle (K) 1 to 3 domains (K1+2+3), may be the concentration of fragment plasminogen comprising kringle (K) 1 to 3 domains (K1+2+3) measured in a biological sample of subject, or the mean concentration value measured in a group of reference healthy subjects. Preferably the reference concentration value of fragments plasminogen comprising kringle (K) 1 to 3 domains (K1+2+3), may be the concentration of fragment plasminogen comprising kringle (K) 1 to 3 domains (K1+2+3) measured in a pool of biological samples from healthy subjects and/or in an internal standard defined as a biological sample of subject titrated against samples from healthy subjects.
According to the invention, the reference concentration value of fragment plasminogen comprising kringle (K) 5 domain and the serine protease (SP) region or mini-plasminogen, (K5-SP), may be the concentration of fragment plasminogen comprising kringle (K) 5 domain and the serine protease (SP) region or mini-plasminogen, (K5-SP) measured in a biological sample of subject, or the mean concentration value measured in a group of reference healthy subjects. Preferably the reference concentration value of fragment plasminogen comprising kringle (K) 5 domain and the serine protease (SP) region or mini-plasminogen, (K5-SP), may be the concentration of fragment plasminogen comprising kringle (K) 5 domain and the serine protease (SP) region or mini-plasminogen, (K5-SP) measured in a pool of biological samples from healthy subjects or in an internal standard defined as a biological sample of subject titrated against samples from healthy subjects.
In the present document, “reference healthy subject” or “healthy subject” is intended to mean a mammal, for example a human being, that has not been subject to an infection, shock, hemorrhage, septic shock and/or any other attack on the body capable of leading to fibrinolytic insufficiency and disseminated intravascular coagulation as defined above. It may be for example a human being, which has not been subject to an infectious or non-infectious pathology associated with NETs or Netosis, for example sepsis, ischemic stroke, coronary thrombosis, cancer, and autoimmune diseases as defined above.
According to the invention, “group of reference subjects” or “group of reference healthy subjects” is intended to mean a group making it possible to define a reliable reference value or reliable reference intervals. It may for example be a group comprising at least 2 reference subjects as defined above, for example at least 10, at least 40, at least 60, at least 100 reference subjects or healthy subjects. It may for example be a group comprising from 30 to 500 subjects, from 40 to 200, from 45 to 110 reference subjects or healthy subjects.
Advantageously, the inventors have demonstrated that when the measured concentration of plasminogen is lower than the reference value or intervals, the process according to the invention makes it possible to detect and/or predict disseminated intravascular coagulation with a fibrinolytic insufficiency.
Advantageously, the inventors have also demonstrated that when the content/concentration of plasminogen fragment is greater than the reference value or intervals, the process according to the invention makes it possible to detect and/or predict inhibition of fibrinolysis and/or fibrinolytic insufficiency, in particular fibrinolytic insufficiency in disseminated intravascular coagulation.
Advantageously, the inventors of the present invention have also demonstrated that the process for detecting fibrinolytic insufficiency comprising measuring the concentration of plasminogen and/or at least one fragment thereof enables detection of fibrinolytic insufficiency.
Advantageously, the inventors have demonstrated that when fragments of plasminogen, preferably mini-plasminogen (K5-SP) are detected in plasma in particular the process according to the invention makes it possible to detect and/or predict pathologies with NETs, for example sepsis, ischemic stroke, coronary thrombosis, cancer, and autoimmune diseases from a first biological sample or associated with Netosis.
Advantageously, the inventors of the present invention have also demonstrated that the process for detecting fibrinolytic insufficiency comprising measuring the concentration of plasminogen and/or at least one fragment thereof enables detection of pathology associated with NETs.
An object of the invention is also an in-vitro process for determining the efficacy of a treatment of fibrinolytic insufficiency associated to DIC and/or pathology associated with NETs, preferably sepsis, ischemic stroke, coronary thrombosis, cancer, and autoimmune diseases and/or pathology associated with Netosis comprising:
S=C2/C1.
According to the invention, the biological sample is a biological sample as defined above.
According to the invention, the biological sample before treatment is a biological sample as defined above.
According to the invention, the biological sample before treatment is a biological sample as defined above.
According to the invention, the determination and/or measurement of the concentration of Plasminogen and/or fragment may be carried out by any method/process as defined/described above.
According to the invention plasminogen's fragment may be any plasminogen fragment as defined/described above.
According to the invention, when the process determines the efficacy of a treatment of fibrinolytic insufficiency and the biological marker is plasminogen, the treatment is effective when the value of S obtained from the comparison step is greater than 1.
According to the invention, when the process determines the efficacy of a treatment of fibrinolytic insufficiency and the biological marker is plasminogen fragment, the treatment is effective when the value of S obtained from the comparison step is lower than 1.
According to the invention, the in-vitro process for determining the efficacy of a treatment with a compound of fibrinolytic insufficiency associated to DIC and/or pathology associated with NETs, preferably sepsis, ischemic stroke, coronary thrombosis, cancer, and autoimmune diseases and/or pathology associated with Netosis comprising:
S=C2/C1,
SF=C2F/C1F
According to the invention, when the process determines the efficacy of a treatment of fibrinolytic insufficiency and the biological marker is plasminogen, the treatment is effective when the value of S obtained from the comparison step is greater than 1.
According to the invention, when the process determines the efficacy of a treatment of fibrinolytic insufficiency and the biological marker is plasminogen fragment, the treatment is effective when the value of SF obtained from the comparison step is lower than 1.
According to the invention, the first biological sample before treatment is a biological sample as defined above.
According to the invention, the second biological sample before treatment is a biological sample as defined above.
According to the invention, the second biological sample before treatment may be identical to or different from the first biological sample before treatment.
According to the invention, the first and second biological samples before treatment may be the same sample.
According to the invention, the third biological sample after treatment is a biological sample as defined above.
According to the invention, the fourth biological sample after treatment is a biological sample as defined above.
According to the invention, the third biological sample after treatment may be identical to or different from the fourth biological sample after treatment.
According to the invention, the third and fourth biological samples after treatment may be the same sample.
In the present “Treatment with a compound” means medical treatment, for example e.g. allopathic, involving the taking of molecules, e.g. chemical molecules, e.g. molecules obtained by organic synthesis, molecules of biological origin, e.g. proteins, molecules from and/or synthesized by living organisms, e.g. mammals, microorganisms, plants, or any other non-chemical treatment or any other device delivering the above mentioned molecules for example nanovesicles, engineered or not, for example conveying native plasminogen.
The inventors have surprisingly demonstrated that the supply of plasminogen to plasma samples of patients with septic shock-induced DIC allows to restore plasmin formation and fibrinolysis.
An object of the present invention is native and/or recombinant Plasminogen for use as a drug in the treatment of fibrinolytic insufficiency, in particular fibrinolytic insufficiency induced by low plasminogen concentration in patients with netosis and/or disseminated intravascular coagulation (DIC).
Also, an object of the present invention is a Pharmaceutical composition comprising Plasminogen for use as a medicament in the treatment of fibrinolytic insufficiency preferably associated to disseminated intravascular coagulation (DIC)
An object of the present invention is also a pharmaceutical composition comprising native and/or recombinant Plasminogen for use as a drug in the treatment of fibrinolytic insufficiency, preferably fibrinolytic insufficiency induced by low plasminogen concentration in patients with netosis and/or disseminated intravascular coagulation (DIC)
Another object of the present invention is Plasminogen, native and/or recombinant, for use as a drug in the treatment of disseminated intravascular coagulation (DIC), for example DIC linked to moderate/severe plasminogen consumption/deficiency, particularly in patients with septic shock induced DIC.
An object of the present invention is a pharmaceutical composition comprising plasminogen, native and/or recombinant, for use as a medicament in the treatment of disseminated intravascular coagulation (DIC), for example DIC linked to moderate/severe plasminogen consumption/deficiency, particularly in patients with septic shock and DIC.
In the present, the terms “treatment,” “treat,” “treated” or “treating” refer to prophylaxis and/or therapy, particularly wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the development and/or progression of disseminated intravascular coagulation. Beneficial or desired clinical results include, but are not limited to improve organs failure, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and healing (whether partial or total). “Treatment” can also mean prolonging survival and/or increased quality of life compared to expected survival and/or quality of life if not receiving treatment.
A “subject” or “patient” includes a mammal, e.g., a human, including a mammal in need of treatment for a disease or disorder, such as a mammal having been diagnosed with having a disease or disorder or determined to be at risk of developing a disease or disorder.
The pharmaceutical composition may be in any form that can be administered to a human or an animal.
The pharmaceutical composition may comprise plasminogen, for example a native and/or recombinant plasminogen. For example it may be Glu-plasminogen at a concentration of 6.6 mg/kg of subject.
Administration may be carried out directly, i.e. pure or substantially pure, or after mixing of plasminogen and/or fragment thereof with a pharmaceutically acceptable carrier and/or medium. According to the present invention, the pharmaceutical composition may be a syrup or an injectable solution. For example, when the pharmaceutical composition is an injectable solution it may be injected and/or administered as a 10- to 30-minute intravenous infusion.
According to the present invention, the pharmaceutical composition comprising plasminogen may be administered every day, two day, three days. . . . One skilled in the art, taking into consideration its technical knowledge would adapt the frequency of administration of the pharmaceutical composition comprising plasminogen.
According to the present invention, when the fibrinolytic insufficiency is associated to netosis, the pharmaceutical composition may be tear drops or any preparation adapted to external application.
According to the present invention, the pharmaceutical composition may be a pharmaceutical composition for oral administration selected from the group comprising a liquid formulation, an oral effervescent dosage form, an oral powder, a multiparticle system, an orodispersible dosage form. For example, when the pharmaceutical composition is for oral administration, it may be in the form of a liquid formulation selected from the group comprising a solution, a syrup, a suspension, an emulsion and oral drops. When the pharmaceutical composition is in the form of an oral effervescent dosage form, it may be in a form selected from the group comprising tablets, granules, and powders. When the pharmaceutical composition is the form of an oral powder or a multiparticulate system, it may be in a form selected from the group comprising beads, granules, mini tablets and micro granules. When the pharmaceutical composition is the form of an orodispersible dosage form, it may be in a form selected from the group comprising orodispersible tablets, lyophilized wafers, thin films, a chewable tablet, a tablet and a capsule, a medical chewing gum. According to the present invention, the pharmaceutical composition may be for buccal and sublingual routes, for example selected from the group comprising buccal or sublingual tablets, muco adhesive preparation, lozenges, oro-mucosal drops and sprays.
According to the present invention, when the fibrinolytic insufficiency is associated to netosis, the pharmaceutical composition may be for topical-transdermal administration, for example selected from the group comprising ointments, cream, gel, lotion, patch and foam.
According to the present invention, the pharmaceutical composition may be formulated for nasal administration, for example selected from the group comprising nasal drops, nasal spray, nasal powder. According to the present invention, the pharmaceutical may be formulated for rectal administration, for example suppository or hard gelatin capsule. According to the present invention, the pharmaceutical composition may be for parenteral administration, for example subcutaneous, intramuscular, intravenous administration. The skilled person in the art understands clearly that the term “form” as used herein refers to the pharmaceutical formulation for its practical use.
The pharmaceutically acceptable carrier may be any know pharmaceutically carrier used for the administration of native or recombinant plasminogen, depending on the subject. For example, pharmaceutically acceptable carrier, diluent or excipient includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent or emulsifier.
The form of the pharmaceutical composition may be selected with regards to the human or animal to be treated.
In another aspect, the present invention provides a method of treating a subject suffering from DIC, in particular DIC during septic shock. This method may comprise the step of administering to said subject native and/or recombinant plasminogen.
Native or recombinant plasminogen, as well as usable formulations are as defined above. The administration can be made by using any pharmaceutical way known by the skilled person and useful to administrate native and/or recombinant plasminogen, preferably the administration is a parenteral administration, preferably intravenous administration. Examples of administrable forms of medicament/drug are provided above.
Other advantages may become apparent to those skilled in the art on reading the examples below, illustrated by the appended figures, given by way of illustration.
Activation of platelets and neutrophils in septic shock results in the formation of microvascular clots containing an intricate scaffold of fibrin with neutrophil extracellular traps (NETs). NETs contain multiple components that might impact endogenous fibrinolysis resulting in failure to lyse clots in the microcirculation and residual systemic microthrombosis. Fibrin-NETs matrices were prepared by seeding and activating neutrophils onto a fibrin surface, and monitored plasminogen activation or degradation was constructed. We demonstrate that the elastase activity of HNE-DNA complexes is protected from inhibition by plasma antiproteases and sustain its ability to degrade plasminogen. Using mass spectrometry proteomic analysis, plasminogen fragments composed of kringle (K) domains (K1+2+3, K1+2+3+4) and the serine protease (SP) region (K5-SP) were identified. The inventors further demonstrate that septic shock patients with disseminated intravascular coagulation have circulating HNE-DNA complexes, HNE-derived plasminogen fragments, a low plasminogen concentration, and a reduced capacity to generate plasmin onto fibrin. The inventors demonstrate that NETs bearing active HNE-DNA complexes reduce plasminogen into fragments thus impairing fibrinolysis by decreasing the local plasminogen concentration, plasminogen binding to fibrin and localized plasmin formation. Thus the reservoir of human neutrophil elastase (HNE) on NETs directly interfere with the fibrinolytic mechanism via a plasminogen proteolytic pathway.
Seven patients (mean age 74.5±10 years) referred for septic shock with multiple organ failure (mean Sequential Organ Failure Assessment SOFA score 13±2) (30) and presenting disseminated intravascular coagulation (DIC) diagnosed during the first 24 h after admission according to the Japanese Association for Acute Medicine JAAM 2016 score (31) were enrolled, as well as ten healthy individuals (Trial Registration: Clinicaltrial.gov identifier NCT #02391792). The Strasbourg University Hospital Ethics Committee approved this study. Informed consent was obtained from the patient or relatives at admission and confirmed by the patient as soon as possible. Platelet-free plasma was prepared from blood collected in 0.13 M sodium citrate (Vacutainer™, Becton Dickinson) by a double centrifugation step (2500 g for 15 minutes), aliquoted and immediately frozen at −80° C. Regular haemostasis studies, and detection of HNE-α1PI and plasmin-α2-antiplasmin complexes were assessed in human plasmas.
Human Glu-plasminogen was purified as described and was over 99% pure as assessed by SDS/PAGE and by amino-terminal sequence analysis (3, 32). Plasminogen elastase-derived fragments of plasminogen were prepared by incubating for 30 min at 37° C., 10 μM of the purified protein with 250 nM of purified HNE. The reaction was stopped by addition of 5 mM PMSF. Fragments were then isolated by affinity chromatography on Lysine-Sepharose. Fibrinogen was purified from fresh-frozen human plasma and characterized as described. (33) Human tPA (>95% single-chain) was obtained from Biopool (Uppsala, Sweden). HNE and the elastase inhibitor α1PI were from Calbiochem (Merck KGaA, Darmstadt, Germany). A sheep polyclonal antibody directed against plasminogen and a monoclonal IgG1 antibody directed against plasminogen kringle 1 (CPL15) were produced and characterized previously.(34, 35) Horseradish peroxidase (HRP)-conjugated CPL15 mAb was obtained using a peroxidase labelling kit according to the manufacturer's instructions (Roche, Mannheim, Germany). The polyclonal rabbit anti-sheep (HRP)-conjugated IgG was from DakoCytomation (Glostrup, Denmark).
Venous blood from healthy volunteers was collected on Acid-Citrate-Dextrose by the Blood Donor Center (Etablissement Français du Sang). Neutrophils were isolated from the anticoagulated blood as described. (36) Briefly, leukocytes were separated from red cells on a separating medium containing 9% Dextran T-500 in Radioselectan. After red cell sedimentation, the leukocyte suspension was centrifuged on Pancoll 1077. The cell pellet was washed with phosphate-buffered saline and contaminating erythrocytes were removed by hypotonic lysis. Polymorphonuclear neutrophils (PMN) were then resuspended in RPMI-1640 or Hank's balanced salt solution (HBSS) (see below) and used immediately after isolation. Flow cytometry showed the absence of CD14+, CD3+, CD19+ cells, confirming the recovery of highly purified PMN (CD16+) that were identified by nuclear morphology on May-Grunwald-Giemsa staining (not shown). Routinely, the purity of neutrophil preparations and cell viability (Trypan blue) were ≥98%. Isolated neutrophils were re-suspended in RPMI-1640 medium or HBSS at a concentration allowing distribution of 200 000 cells per well. Experiments were performed on 96-well flat-bottomed plates containing or not a well-defined fibrin surface prepared and characterized as described below.
Since PMA and bacteria use related pathway (protein kinase C activation and generation of reactive oxygen species for induction of proteolytically active NETs), we used the well standardized technique of PMA stimulation.(14) After 1 hour, plated neutrophils were treated with 50 nM PMA in a humidified 5% CO2 atmosphere at 37° C., during 4 hours. NETs were identified by (1) DNA staining with a 10 μg/ml solution of Hoechst 33342 and (2) measuring the activity of DNA-bound elastase.
Stained nuclei of non-stimulated neutrophils and PMA-induced extracellular traps were detected in optic fields of three wells for each condition using the X20 objective of a Zeiss AxioObserver D1 fluorescence microscope equipped with a CCD Imaging camera using the Histolab software from Microvision Instruments (Evry, France).
To detect elastase bound to NETs, the substrate MeO-Suc-AAPV-pNA (100 μl per well, 1.5 mM final concentration in HBSS) was incubated with NETs after two gentle washes with HBSS. DNA-bound HNE activity was detected in a multi-well plate counter at 37° C. by measuring the release of p-nitroaniline (pNA) at A405 nm. The elastase inhibitors MeO-Suc-AAPV-CMK (100 μM final) or α1-PI (10 μM final) and AEBSF (1 mM) were used to authenticate preservation of DNA-bound elastase activity.
Fibrin matrices were prepared as described previously (WO/1985/004425). (34, 37, 38) Briefly, a monolayer of fibrinogen was immobilised onto poly(glutaraldehyde)-activated flat-bottomed 96-well plates. The immobilised fibrinogen (410±4 fmol/cm2) was transformed into fibrin using a 10 N.I.H. u/ml solution of thrombin containing 2 mM CaCl2). The release of fibrinopeptide A was followed using the monoclonal antibody Y18.(39) Fibrin thus obtained specifically interacts with the finger domain of tPA whereas plasminogen binds to newly exposed carboxy-terminal lysine residues unveiled during on-going fibrin degradation.(3, 33, 37) Fibrin degradation was followed with mAb DD3B6 specific for D-dimer structures unveiled by plasmin on the immobilised fibrin.(40) Advantageously fibrin-NETs matrices could be alternatively prepared using a variety of supports, for example beads or slides.
The chromogenic substrate selective for plasmin (methylmalonyl)hydroxyprolylarginine—p-nitroanilide (CBS0065) was kindly provided by G. Contant (Diagnostica Stago, Asnières, France). Phorbol 12-myristate 13-acetate (PMA), the serine protease inhibitors aminoethyl-benzene-sulfonyl fluoride (AEBSF) and phenylmethylsulphonyl fluoride (PMSF), the elastase-specific substrate N-methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (MeO-Suc-AAPV-pNA) and the elastase-specific inhibitor N-methoxysuccinyl-L-alanyl-L-alanyl-L-prolyl-valine-chloromethyl ketone (MeO-Suc-AAPV-CMK) were from Sigma-Aldrich (L'Isle d'Abeau-Chenes, France). Hank's balanced salt solution (HBSS) was from Gibco. Dextran T-500 from Serva. Radioselectan was from Schering, France. Pancoll 1.077 mg/ml was from PAN BIOTECH GmbH (distributed by Dutscher, Brumath, France). Hoechst 33342, a minor groove binder of dsDNA was from BioProbes (distributed by ThermoFisher, France).
Human neutrophil elastase (HNE) was detected as a complex with the @1-proteinase inhibitor (α1-PI) using the Human PMN Elastase Platinum ELISA kit from Affymetrix (Bender MedSystems GmbH, Vienna, Austria). Plasmin-α2-antiplasmin complexes were detected by ELISA (Technozym, Technoclone GmnH, Vienna, Austria).
Samples used were either purified proteins (human plasminogen, plasmin and HNE-derived plasminogen fragments) or plasma protein fractions of interest (euglobulins and lysine-affinity fractions) depleted in highly abundant proteins. The euglobulin fraction from 100 μl of plasma (patients or control) was precipitated at low ionic strength and pH 5.8 in the presence of protease inhibitors and resuspended in 2.5% SDS, 62.5 mMTris-HCl PH 6.8 sample buffer; this fraction is depleted in albumin and α-globulins but contains all β- and γ-globulins including plasminogen and its fragments. Proteins bound to lysine-Sepharose from 3 ml of plasma (pool of plasma from 6 patients) were eluted with 30 mM ε-aminocaproic acid as previously described.(66) The lysine-affinity fraction specifically contains proteins bearing a lysine-binding site.
Proteins in samples were separated on either 8% or 15% SDS-PAGE gels. Bands were manually excised from gels and were cut into cubes. Then, in-gel digestion was carried out with trypsin, according to a published procedure with minor adjustments (67): sample were destained twice with a mixture of 100 mM ammonium bicarbonate (ABC) and 50% (vol/vol) acetonitrile (ACN) for 30 min at room temperature and then dehydrated using 100% ACN for 20 min, before being reduced with 25 mM ABC containing 10 mM DTT for 1 h at 57° C. and alkylated with 55 mM iodoacetamide in 25 mM ABC for 30 min in the dark at room temperature. Gel pieces were washed twice with 25 mM ABC and dehydrated (twice, 20 min) with 100% ACN. Gel cubes were incubated with sequencing grade-modified trypsin (Promega, USA; 12.5 ng/μl in 40 mM ABC with 10% ACN, pH 8.0) overnight at 37° C. After digestion, peptides were extracted twice from gel pieces with a mixture of 50% ACN-5% formic acid (FA) and then with 100% ACN. Extracts were dried using a vacuum centrifuge concentrator plus (Eppendorf).
Mass spectrometry analyses were performed using an Ultimate 3000 Rapid Separation Liquid Chromatographic (RSLC) system (Thermo Fisher Scientific) online with a Q Exactive hybrid quadrupole Orbitrap mass spectrometer (ThermoFisher Scientific). Briefly, peptides were solubilized in 3.5 μL of 10% ACN-0.1% TriFluoroAcetic acid (TFA). Then, peptides were loaded and washed on a C18 reverse-phase precolumn (3 μm particle size, 100 Å pore size, 75 μm i.d., 2 cm length). The loading buffer contained 98% H2O, 2% ACN and 0.1% TFA. Peptides were then separated on a C18 reverse-phase resin (2 μm particle size, 100 Å pore size, 75 μm i.d., 25 cm length) with a 30 min gradient from 99% A (0.1% FA and 100% H2O) to 40% B (80% ACN, 0.085% FA and 20% H2O).
The mass spectrometer acquired data throughout the elution process and operated in a data-dependent scheme with full MS scans acquired with the Orbitrap, followed by up to 10 MS/MS HCD spectra in the Orbitrap. Mass spectrometer settings were: full MS (AGC: 3×10e6, resolution: 7×10e4, m/z range 400-2000, maximum ion injection time: 100 ms) and MS/MS (AGC: 1×10e5, maximum injection time: 100 ms, isolation window: 4 m/z, dynamic exclusion time setting: 15 s). The fragmentation was permitted for precursors with a charge state of +2, 3 and 4. For the spectral processing, the software used to generate .mgf files was Proteome discoverer 1.4 (ThermoFisher Scientific). Database searches were carried out using Mascot version 2.5.1 (Matrix Science, London, UK) on ‘human’ proteins (20,273 sequences) from the SwissProt databank containing 550,552 sequences (196,472,675 residues) (February 2016). The search parameters were as follows: the enzyme specificity as semiTrypsin, carbamidomethylation as a fixed modification for cysteins and oxidation as a variable modification for methionines. Up to 1 missed cleavage was tolerated, and mass accuracy tolerance levels of 4 ppm for precursors and 20 mmu for fragments were used for all tryptic mass searches. Positive identification was based on a Mascot score above the significance level (i.e. 5%). The reported proteins were always those with the highest number of peptide matches.
Fibrin-NETs matrices were achieved by activation with PMA of neutrophils seeded onto fibrin surfaces prepared as described above. The neutrophils were seeded onto the fibrin matrix at 200 000 cells per well and were stimulated with PMA after 1 h plating as indicated above. After 4 h of stimulation a fibrin-NETs matrix was obtained as visualized by Hoechst staining and elastase activity detection (
Plasminogen was quantified with a functional activity assay as described with modifications.(41) Briefly, plasmas were diluted 1:50 in assay buffer (Phosphate 80 mM, NaCl 50 mM, BSA 2 mg/ml), supplemented with 75 i.u./ml urokinase, 1 mM tranexamic acid and 0.75 mM of the plasmin-selective chromogenic substrate in a final volume of 50 μl. Kinetics of the reaction was followed by measuring the release of pNA at A405 nm in a microplate photometer in kinetics mode. Results were given in nM concentration by reference to a standard curve prepared with plasminogen-depleted plasma supplemented with known concentrations of purified plasminogen (0.2 to 1 μM). Plasminogen fragments present in plasma were initially detected by Western blot as indicated above. Further identification was obtained by mass spectrometric (see above). Plasmin formation on fibrin matrices was measured using the euglobulin fraction from healthy control and patient plasmas as source of plasminogen as indicated above. Plasminogen activation onto the fibrin-NET matrices. Kinetics of plasminogen transformation into plasmin was followed during 1 h by measuring the release of pNA at A405 nm and the initial velocity of the reactions were calculated as indicated above.
Plasma HNE-DNA complexes of NETs were identified using an ELISA capture assay as described (19) with the following modifications. Since HNE is the enzyme involved in plasminogen fragmentation and is also the most abundant granular component of NETs, we choose to capture HNE-DNA complexes using an anti-HNE antibody. The antibody (10 μg/ml) was immobilized on poly(glutaraldehyde)-activated U 96-well polyvinyl chloride plates as described above for fibrinogen. A volume of 50 μl of diluted human plasma was added per well in combination with the peroxidase-labeled anti-DNA monoclonal antibody (component No. 2 of the commercial cell death detection ELISA kit) according to the manufacturer's instructions (Roche Diagnostic, Mannheim, Germany). After 1 h incubation at 37° C., the samples were washed three times with 100 μl PBS per well and 100 μl/well of the peroxidase substrate ABTS at 1 mg/ml were added. The absorbance at 405 nm wavelength was measured at 37° C. in the dark using a multi-well plate photometer as indicated above.
NETs Released onto a Fibrin Matrix Form a Dense Lattice
NETs were identified as extracellular fibrillar networks primarily composed of DNA stained by Hoechst dye. Further identification was achieved by detecting HNE bound to DNA using an activity assay (
NETs' HNE•DNA Complexes Cleave Plasminogen into Well-Defined Fragments
It is well-known that HNE in solution (purified or released by neutrophils) produces plasminogen fragments of known structure (4, 44). However, it remains unknown whether HNE bound to NETs is able to cleave plasminogen into fragments. To investigate this hypothesis, we incubated plasminogen with lattices of NETs spread on the fibrin matrix.
NETs HNE-Derived Plasminogen Fragments Interfere with Fibrinolysis
Having demonstrated that HNE•DNA complexes of NETs cleave plasminogen into fragments K1+2+3, K4 and K5-SP, the critical question of their role in fibrinolysis was sought to be answer. For that purpose, neutrophils seeded onto a fibrin matrix were prompted to release NETs with PMA as above. Conversion of plasminogen into plasmin by tPA bound to the fibrin-NET lattice was then assessed using a plasmin-selective chromogenic substrate. The time- and concentration-dependent conversion of plasminogen into plasmin at the fibrin-NETs lattice was reduced as compared to fibrin alone (
Results of the parameters tested are shown in Table 1 below.
NETS were detected by measuring HNE•DNA complexes in samples from patients with septic shock and disseminated intravascular coagulation (patients 0.276±0.043; healthy controls: 0.086±0.014, A405 nm). The concentration of plasminogen as measured with a functional assay was 520±180 nM (healthy controls n=31: 1.69±0.33 μM). Circulating HNE•α1-PI complexes were increased 8-fold in patients as compared to healthy controls, 437±274 versus 43±19 ng/ml, respectively. Patients had elevated D-dimers (12±8 mg/l) and plasmin-α2-antiplasmin (range 4814-159 ng/ml, median 1207 ng/ml), without signs of hepatic dysfunction, although moderate cytolysis. The presence of HNE-derived plasminogen fragments was evidenced by SDS-PAGE and Western blotting.
To investigate the effect of NETs and plasminogen fragments on fibrinolysis, the euglobulin fraction of septic shock plasma samples were incubated with tPA bound to fibrin surfaces and the amount of plasmin formed was quantified with a chromogenic substrate. The generation of plasmin was decreased (>50%) when comparing different septic shock plasma to a pool of normal plasma (
Netosis, a major antimicrobial mechanism, has alternative roles in both infectious and non-infectious diseases. In septic shock, for instance, activated neutrophils emit extracellular traps that both ensnare pathogens and activate coagulation leading to fibrin formation. The microvascular clots that ensue, a mechanism referred to as immunothrombosis, favor pathogens circumscription and killing by NETs enzymes. (20, 45, 46) Several actors of this interconnected mechanism between coagulation and innate immunity may also nurture uncontrolled thrombosis and thereby hinder the initial benefit of the response.(47) As a consequence, NETs may substantially contribute to septic shock-associated intravascular coagulation. Actually, we detected circulating NETs in septic shock patients with intravascular coagulation, (48) a finding that was confirmed in recent studies.(49-52). The example is focus on the role of NETs on the other side of the hemostatic equilibrium: the fibrinolytic response.
Using a fluorescent DNA binder, the inventors notice that NETs formed in vitro onto a fibrin surface show a denser and more reticulated appearance than NETs released in the absence of fibrin. The positive charges regularly distributed along the fibrin fibers interact with negatively charged DNA yielding a more dense appearance of DNA fibers in the entangled fibrin-NETs matrix. These findings agree with data previously reported indicating that cell-free DNA incorporated into a clot modifies the structure of fibrin rendering it resistant to plasmin-mediated degradation.(26, 28) The entangled assembly of DNA and fibrin within the thrombus may be implicated in NETs-mediated resistance to tPA-induced fibrinolysis in vitro (21, 29) and thrombolysis in patients with acute ischemic stroke.(54) Such fibrinolytic resistance may contribute to persisting thrombotic occlusion due to sustained platelet activation by histones (21) and inactivation of tissue factor pathway inhibitor (TFPI) by HNE.(45) Actually, the inventors demonstrate that NETs entangled with fibrin contain active HNE in complex with DNA that is insensitive to inhibition by α1-PI. Similarly, NETs-associated murine NE was found to be proteolytically active within the liver vasculature.(55) Contrastingly, elastase bound to the plasma membrane of neutrophils is easily released to form soluble irreversible complexes with circulating α1-PI.(7) The protective function of DNA on HNE activity is in agreement with previous findings indicating that leukocyte granular serine proteases bind to DNA with nanomolar affinity and endow HNE with resistance to plasma inhibitors thus ensuring localized degradation of protein substrates.(9, 11, 12, 17).
The example clearly demonstrates that in the presence of NETs containing active HNE-DNA complexes plasminogen is reduced to fragments of well-defined size: K1+2+3, K1+2+3-4, K4 and K5-SP that have lost their capacity to generate plasmin by fibrin-bound tPA. These plasminogen fragments were detected when plasminogen was added to NETs released by activated neutrophils in-vitro. The nature of the fragments was identified with certainty by mass spectrometric analysis of amino-acid sequences. Since plasminogen fragments bearing K1 have been previously shown to be strong inhibitors of plasminogen binding to fibrin, plasmin generation and fibrinolysis, (56-58) the inventors investigate the role of NETs on these mechanisms. The experimental fibrin-NETs lattice used by the inventors is an outstanding set-up suitable to detect both the NETs-HNE-derived plasminogen fragments and the competitive effect of K1-containing fragments on plasminogen binding and activation. The inventors demonstrate that when plasminogen was activated by fibrin-bound tPA on the NETs-fibrin lattice, a decrease in the amount of plasmin generated by tPA occurred concomitantly with the appearance of such fragments. These data indicate that these plasminogen fragments compete with plasminogen for binding to fibrin decreasing thereby its capacity to generate plasmin.
At variance with the antifibrinolytic effect described here, there are other protein components of hemostasis that could be a substrate for HNE-some of which may have direct or indirect effects on thrombus formation and lysis. In particular, HNE may exert either a procoagulant activity by inactivating TFPI(45) or a profibrinolytic activity by direct cleavage of fibrin, (59) by degrading α2-antiplasmin or PAI-1(60, 61) or by producing mini-plasminogen (K5-SP).(5) Although mini-plasminogen (K5-SP) may be activated by urokinase in solution, it does not bind to fibrin and is therefore not activated by tPA at the fibrin surface; as a consequence, the impact of K5-SP on tPA-fibrin-dependent clot lysis is negligible.(5, 62).
gTaken all together, the results clearly demonstrate that HNE-DNA complexes exert an antifibrinolytic effect by generating plasminogen fragments and decreasing the plasminogen concentration.
The indicators of NET-induced fibrinolytic failure in vitro in plasma samples from septic shock patients with DIC and circulating NETs were investigated. The inventors clearly demonstrate that this group of patients have a low plasminogen concentration, circulating plasminogen fragments and a failure to generate plasmin on fibrin (less than 50% when compared to a pool of normal plasmas) which clearly contribute and/or be responsible for the observed intravascular coagulation and multiple organ dysfunction. Protein bands detected by Western blot and identified by mass spectrometric amino-acid analysis in plasma fraction of the selected patients corresponded to intact plasminogen and plasminogen fragments: K1+2+3, K1+2+3+4 and K5-SP. These fragments were identical to those derived from plasminogen cleaved in vitro by purified HNE.(44).
Since α1-PI circulates at μM concentration and inhibits all free HNE with an extremely high association constant (Ka=6.5×107 M-1 s-1),(6) elastase released by neutrophils was readily found as HNE-α1PI complexes in plasma from septic shock patients. HNE-α1PI complexes are therefore a marker of neutrophil activation in sepsis. The inventors demonstrate that in the absence of active elastase in the plasma of these patients, the plasminogen fragments found in plasma were produced by active HNE-DNA complexes. These data, strongly support a mechanistic pathway where plasminogen fragments found in patients with septic shock were produced locally on the fibrin-NETs matrix of the clot. Nevertheless, besides fibrin, histone H2B bearing carboxyterminal lysines may capture plasminogen in the vicinity of HNE bound to the DNA fibers.(64) Circulating NETs containing active HNE-DNA complexes insensitive to α1-PI could also participate in plasminogen fragmentation.
As demonstrated, the proteolysis of plasminogen by HNE-DNA complexes is in part responsible for the low concentration, less than 1 μM, of full-length plasminogen detected in the plasma of septic shock patients. The low concentration of plasminogen in conjunction with the anti-fibrinolytic activity of plasminogen fragments result in insufficient fibrinolysis in septic shock leading to disseminated intravascular coagulation (DIC). These parameters, plasminogen concentration, plasminogen fragments and failure to form plasmin are relevant new prognostic markers to assess the role of NETs in sepsis and septic shock induced DIC and serve as predictors of mortality and organ failure in septic shock patients.
Since the low plasminogen concentration of these plasmas could explain in part the low fibrinolytic activity, the plasmas were supplemented with plasminogen before testing. In spite of reaching a plasminogen concentration similar to that of the normal plasma pool, 3 out of the 6 plasmas tested failed to restore their fibrinolytic activity to normal values. These results demonstrate a competitive effect towards plasminogen most probably related to the presence of circulating HNE-derived plasminogen fragments containing K1.
The results clearly demonstrate that a severe decrease in fibrinolysis induced by HNE-DNA complexes of NETs contribute to the persistence and stabilization of thrombi in the microcirculation during septic shock.
The inventors also demonstrate that septic shock thrombosis in the microcirculation is in relation with the capacity of HNE-DNA complexes to trigger fibrinolytic insufficiency. Identification of this reduction in the fibrinolytic potential in plasma of septic shock patients, as shown in
The inventors demonstrate that NETs or fragments of NETs contain active elastase responsible for the production of plasminogen fragments with inhibitory activity (competitors of plasminogen binding to fibrin), which act to decrease both the concentration of plasminogen and plasmin formation. Altogether, the low plasminogen and the inhibitory activity of the elastase-derived plasminogen fragments contribute to abrogate the fibrinolytic system, thus favoring microthrombosis and organ failure.
The example clearly demonstrates that the fragmentation of plasminogen by active HNE-DNA complexes and a concomitant decrease in both the concentration of plasminogen, and plasmin formation are required are required to dampen fibrinolysis (
This example clearly demonstrates that the level of plasminogen is a biological marker of the fibrinolytic response associated to DIC, in particular during septic shock.
This example also clearly demonstrates that plasminogen restores fibrinolytic activity in patients suffering netosis and septic shock associated DIC and constitute a new therapeutic treatment for these patients by the supplementation.
Plasminogen is the precursor of plasmin, the enzyme required to dissolve blot clots. Plasminogen is transformed into plasmin by the endothelial plasminogen activator tPA. Plasminogen circulates in blood at a concentration ranging from 1.5 to 2 μmol/L (138 μg/ml to 184 μg/ml), which is in excess over the amount required to generate full plasmin activity by tPA on fibrin. However, at concentrations lower than 1 μM plasminogen is a rate-limiting factor for plasmin generation that may lead to insufficient fibrinolysis (Biochem J 1995).
Indeed, previous studies have shown that the rate of thrombus lysis is limited by the amount of available plasminogen that governs its accumulation onto fibrin (Biochemistry 1991, Thromb Haemostas 1991; J Lab Clin Med 1992, Circulation 1995). A continuous plasminogen supply from the circulation is therefore necessary to ensure its accumulation on the thrombus and sustain the potential for its optimal lysis. However, this supply is restricted in pathological conditions where thrombosis in the microcirculation is combined to an important decrease in plasminogen; a compromised blood flow by insufficient thrombus lysis, may thereby worsen the clinical prognosis.
The example 1 above clearly demonstrates that in patients with septic shock presenting disseminated intravascular clot formation (DIC) the functional plasminogen concentration is found below 1 μM or even lower than 0.5 μM in severe cases (
The decreased plasminogen concentration found in patients with septic shock may result in part from consumption via fibrinolysis secondary to DIC (as indicated by circulating plasmin•α2-antiplasmin complexes and D-dimers plasma concentration). However, the persistence of microthrombi in DIC indicates a failure in the fibrinolytic response.
In septic shock with DIC neutrophils and platelets act in concert to promote coagulation and formation of Neutrophil Extracellular Traps (NETs) in a reciprocal coupling process called immunothrombosis (20, 45). NETs formation is an intermediary mechanism in septic shock (
NETs are DNA fibers bearing elastase, myeloperoxidase and other granular proteins. Unlike free elastase, NET-associated elastase is resistant to the a1-proteinase inhibitor and is therefore able to cleave plasminogen into well-known fragments that have loss its capacity to generate plasmin.
The results clearly demonstrate that the important decrease in the concentration of functional plasminogen detected in septic shock patients with DIC is mainly related to proteolysis by elastase-DNA complexes of NETs. Proteolysis of full-length plasminogen, N-ter region-K1-K2-K3-K4-K5-SP (K: kringle domain, SP: serine-protease region) by elastase gives rise to plasminogen fragments K1+2+3, K1+2+3+4, K4 and K5-SP (also called mini-plasminogen).
The data obtained in a cohort of patients (n=100) show that plasmin generation is importantly decreased in patients with septic shock and low plasminogen as compared to healthy volunteers. The low capacity to form plasmin results in insufficient fibrinolysis that favors the presence of thrombi in the microcirculation (DIC) and the associated multi-organ dysfunction in patients with septic shock. Extensive ischemic tissue damage associated to DIC leads to failure of multiple organs (especially lung, kidney, liver, and brain).
The data on plasmin generation onto the fibrin surface using these plasmas show that mini-plasminogen (K5-SP) beyond being a marker of plasminogen proteolysis by Elastase•DNA is, above all, a source of non-fibrinolytic mini-plasmin, i.e. a contributor of fibrinolytic insufficiency. Plasmas containing mini-plasminogen generate mini-plasmin lacking the ability to bind to fibrin, i.e. easily inhibited by plasma inhibitors and therefore with no specificity for fibrinolysis. As such, K5-SP in plasma interferes with the functional determination of full-length plasminogen and with the assessment of fibrinolysis.
Administration of plasminogen to patients with septic shock having an important decrease of endogenous circulating plasminogen is advantageous to improve effective fibrinolysis, thrombi dissolution and recovery of patient's health. Within this context, plasminogen monitoring (full-length protein and/or its fragments) is a key determinant in assessment of the fibrinolytic response to DIC in septic shock patients and its evolution to organ dysfunction, and in monitoring of plasminogen recovery during on-going replacement therapy with human Glu-plasminogen.
The plasminogen (and/or its fragments) as a key analytic measure in diagnosis and/or follow-up of patients, for example with netosis-associated septic shock, for both the diagnosis of DIC and/or also plasminogen-related fibrinolytic insufficiency and its treatment with plasminogen replacement.
The fibrinolytic and NETs components/parameters are to be assayed in patients with septic shock (n=100) as compared to healthy individuals (n=31)
In addition, the example also clearly supports that the determination of mini-plasminogen (K5-SP) is a direct marker of elastase·DNA activity and is a marker of pathology associated with NETs, for example sepsis, ischemic stroke, coronary thrombosis, cancer, and autoimmune diseases, among others. Assessment of mini-plasminogen by a functional assay may also provide information about its role in fibrinolysis insufficiency.
| Number | Date | Country | Kind |
|---|---|---|---|
| 19306378.1 | Oct 2019 | EP | regional |
| 20174840.7 | May 2020 | EP | regional |
The present application is a filing under 35 U.S.C. 371 as the National Stage of International Application No. PCT/EP2020/079518, filed Oct. 20, 2020, entitled “METHOD FOR DIAGNOSING FIBRINOLYTIC INSUFFICIENCY RELATED TO NEUTROPHIL EXTRACELLULAR TRAPS,” which claims priority to European Application Ser. No. 20/174,840.7 filed with the European Patent Office on May 14, 2020 and also claims priority to European Application No. 19306378.1 filed with the European Patent Office on Oct. 24, 2019, all of which are incorporated herein by reference in their entirety for all purposes.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2020/079518 | 10/20/2020 | WO |
